The latest price target for Ascendis Pharma (NASDAQ:ASND) was reported by Evercore ISI Group on February 18, 2025. The analyst firm set a price target for $260.00 expecting ASND to rise to within 12 months (a possible 70.57% upside). 44 analyst firms have reported ratings in the last year.

The latest analyst rating for Ascendis Pharma (NASDAQ:ASND) was provided by Evercore ISI Group, and Ascendis Pharma maintained their outperform rating.

The last upgrade for Ascendis Pharma AS happened on September 5, 2024 when Oppenheimer raised their price target to $180. Oppenheimer previously had a perform for Ascendis Pharma AS.

The last downgrade for Ascendis Pharma AS happened on April 5, 2023 when Oppenheimer changed their price target from N/A to N/A for Ascendis Pharma AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on February 18, 2025 so you should expect the next rating to be made available sometime around February 18, 2026.

While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a maintained with a price target of $220.00 to $260.00. The current price Ascendis Pharma (ASND) is trading at is $152.43, which is out of the analyst’s predicted range.